Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00317577 · ClinicalTrials.gov registry record · Phase 2
Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma
A Phase 2 study of Glaucoma Open-Angle, sponsored by Chicago Center for Vision Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 12
- Study locations
NCT00317577 is a Phase 2 study of Glaucoma Open-Angle that has completed, run by Chicago Center for Vision Research. The registered enrollment target is 160 participants, roughly in line with the 158-participant average among 22 other Glaucoma Open-Angle trials with a reported enrollment target. The trial reports 12 study locations across 8 states.
The verdict
NCT00317577, a Phase 2 study of Glaucoma Open-Angle, has completed, sponsored by Chicago Center for Vision Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 12
- Study locations
Study Summary
Low-pressure (normal tension) glaucoma is a type of open-angle glaucoma resulting in damage to the optic nerve and abnormalities of the visual field. Eye (intraocular) pressure in this type of glaucoma is not higher than that usually considered to be normal (less than 21 mmHg) for the eye. The present treatment of low-pressure glaucoma is also directed to lowering the "normal" eye pressure. Both medications in this study, brimonidine and timolol, lower eye pressure. Laboratory research over the past decade indicates the potential to treat glaucoma not only by lowering eye pressure, but with treatments aimed at the damage occurring at the optic nerve. One group of drugs, selective alpha2-adrenergic agonists, have been shown in laboratory animals to protect against the effects of nerve damage following local stroke. Brimonidine, one of the medications in the current study, is a selective alpha2-adrenergic agonist which protects against damage to optic nerve in animal models of glaucoma.. The hypothesis of the present study is that brimonidine eye drops provide protection to the damaged optic nerve independent of lowering eye pressure in patients with low-pressure glaucoma. This will be determined by (1) measuring eye pressure, (2) performing visual field examinations, and (3) examination of the optic nerve.
Conditions Studied
Interventions
- DRUG brimonidine, timolol
Study Locations (12)
Illinois
- University Eye Specialists - Chicago
- University of Chicago - Chicago
- Wheaton Eye Clinic - Wheaton
Florida
- University of Florida - Gainesville
- Bascom Palmer Eye Institute - Palm Beach Gardens
Pennsylvania
- Scheie Eye Institute University of Pennsylvania - Philadelphia
- Wills Eye Hospital - Philadelphia
Arkansas
- Little Rock Eye Clinic - Little Rock
Indiana
- Indiana University - Indianapolis
New York
- New York Eye & Ear Infirmary - New York
South Dakota
- Black Hills Regional Eye Institute - Rapid City
Texas
- Cullen Eye Institute Baylor University - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 1998-12 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00317577
The ClinicalTrials.gov registry entry for NCT00317577 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 158-participant average among 22 other Glaucoma Open-Angle trials with a reported enrollment target. The listed sponsor is Chicago Center for Vision Research, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma Open-Angle appearing as the primary indexed condition, and to 1 intervention - of which brimonidine, timolol is the first listed.
NCT00317577 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Illinois, Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00317577 about?
NCT00317577 is a clinical study titled "Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma". Low-pressure (normal tension) glaucoma is a type of open-angle glaucoma resulting in damage to the optic nerve and abnormalities of the visual field. Eye (intraocular) pressure in this type of glaucoma is not higher than that usually considered to be normal (less than 21 mmHg) for the eye. The prese...
What is the current status of trial NCT00317577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 1998-12. Estimated completion is 2004-05.
What conditions does trial NCT00317577 study?
This clinical trial studies the following conditions: Glaucoma Open-Angle.
What interventions are being tested in trial NCT00317577?
The interventions under investigation include: brimonidine, timolol (DRUG).
Who is sponsoring clinical trial NCT00317577?
This trial is sponsored by Chicago Center for Vision Research, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00317577 being conducted?
This trial has 12 study locations across Arkansas, Florida, Illinois, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma Open-Angle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Safety and Efficacy of a Glaucoma Drug Delivery System
COMPLETED · Phase 2
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
-
Electrical Stimulation for Vision Neuroenhancement in Glaucoma
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Optic Neuropathies
RECRUITING · NA
-
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.